PDS Biotechnology Announces Conference Call and Webcast to Present Second Quarter 2021 Financial Results

Posted on July 26, 2021 by Admin

PDS Biotechnology Announces Conference Call and Webcast to Present Second Quarter 2021 Financial Results

FLORHAM PARK, N.J., July 26, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune^® T-cell activating technology, will release financial results for the second quarter of 2021 on Thursday, August 12, 2021, before the market opens. Following the release, management will host a conference call to review the company’s financial results and provide a business update.

The conference call is scheduled to begin at 8:00 am ET on Thursday, August 12, 2021. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotechnology. A live webcast of the conference call will also be available on the investor relations page of the Company’s corporate website at www.pdsbiotech.com.

After the live webcast, the event will be archived on PDS Biotech’s website for 6 months. In addition, a telephonic replay of the call will be available for 6 months. The replay can be accessed by dialing 877-660-6853 (United States) or 201-612-7415 (International) with confirmation code 13721612.

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Company’s proprietary Versamune^® T-cell activating technology platform. Our Versamune^®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells capable of targeting and killing tumors. Our immuno-oncology product candidates are initially being studied in combination therapy to potentially enhance efficacy without compounding toxicity across a range of cancer types. The company’s lead investigational cancer immunotherapy product PDS0101 is currently in three (3) Phase 2 clinical studies in HPV-associated cancers. Interim data for the company’s most advanced Phase 2 trial was reported in an oral presentation at the recent American Society of Clinical Oncology (ASCO) on June 7, 2021. The interim results demonstrated strong efficacy in treating the cancer in patients with advanced, treatment-resistant HPV16-positive anal, cervical, head and neck, vaginal and vulvar cancers. PDS Biotech has developed multiple therapies, based on combinations of Versamune^® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The company’s pipeline products address various cancers including breast, colon, lung, prostate and ovarian cancers. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

CONTACT: Media & Investor Relations Contact:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital

Virtual Roadshow with CoreCivic (CXW) CEO Damon Hininger and CFO David Garfinkle

Posted on July 26, 2021 by Admin

CoreCivic CEO Damon Hininger and CFO David Garfinkle make a formal corporate presentation. Afterwards, they are joined by Noble Capital Markets Senior Research Analyst Joe Gomes for a Q & A session featuring questions asked by the live audience throughout the event.

Research, News, and Advanced Market Data on CXW

Information on upcoming live virtual roadshows

About CoreCivic

CoreCivic is a diversified government solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. CoreCivic provides a broad range of solutions to government partners that serve the public good through corrections and detention management, a network of residential reentry centers to help address America’s recidivism crisis, and government real estate solutions. CoreCivic is the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believes it is the largest private owner of real estate used by government agencies in the U.S. CoreCivic has been a flexible and dependable partner for government for more than 35 years. CoreCivic’s employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good.

enCore Energy Announces Group 11 Technologies Update and Webinar

Posted on July 26, 2021 by Admin

enCore Energy Announces Group 11 Technologies Update and Webinar

July 26, 2021 – Corpus
Christi, Texas – enCore Energy Corp. (TSXV: EU; OTCQB:ENCUF) (the “Company”) is pleased to advise that Group 11 Technologies Inc., a private US-based company held 40%, pre-financing, by enCore Energy, has completed a USD $1 million financing with accredited investors. Proceeds will advance test work to assess the amenability and recovery rates for gold extraction through the combination of in situ recovery technology and an environmentally friendly water-based solution.

Management of GFG and Group 11 will host a webcast on Monday, July 26, 2021, at 2:30 pm Eastern Standard Time (11:30 am Pacific Standard Time) to discuss Group 11’s innovative technology and the upcoming programs. To register please visit: https://my.6ix.com/event/gfg-and-group11/

After registering, you will receive a confirmation email containing details to access the webinar via conference call or webcast. A replay of the webcast will be available following the conclusion of the call.

About Group 11
Technologies Inc.

Group 11 is a private US-based company committed to the development and application of environmentally and socially responsible precious metals mineral extraction. The combination of in-situ recovery extraction (ISR) technology and environmentally friendly water based chemistry to recover gold and other metals provides a promising alternate solution to conventional open pit and underground mineral extraction. The goal of advancing sustainable extraction considers growing concerns surrounding water use and discharge, carbon footprint, energy consumption, community stakeholders and workplace safety while addressing a growing global need for metals in our daily lives. Group 11 was founded by Enviroleach Technologies Inc. (CSE: ETI; OTCQB: EVLLF), Encore
Energy Corp. (TSXV: EU; OTCQB: ENCUF) and Golden Predator Mining Corp. (TSXV: GPY; OTCQB: NTGSF).

Group 11 is a group of elements in the periodic table, also known as the
coinage metals, consisting of gold (Au), silver (Ag) and copper (Cu).

About enCore Energy
Corp.

enCore Energy Corp. is a U.S. domestic uranium developer focused on becoming a leading in-situ recovery (ISR) uranium producer. The Company is led by a team of industry experts with extensive knowledge and experience in the development and operations of in situ recovery uranium operations. enCore Energy’s opportunities are created from the Company’s transformational acquisition of its two South Texas production facilities, the changing global uranium supply/demand outlook and opportunities for industry consolidation. These short-term opportunities are augmented by our strong long term commitment to working with local indigenous communities in New Mexico where the company holds significant uranium resources. enCore Energy also holds 35.3% of Group 11 Technologies Inc.

For additional information:

William M. Sheriff

Executive Chairman

972-333-2214

info@encoreenergycorp.com

www.encoreenergycorp.com

QuickChek – July 26, 2021

Posted on July 26, 2021 by Admin

Comtech Telecommunications Corp. Awarded $35.8 Million Contract to Deploy Next Generation 911 Technologies and Services

Comtech Telecommunications announced that during its fourth quarter of fiscal 2021, its Safety & Security Technologies group was awarded a multi-year statewide contract valued at $35.8 million

Research, News & Market Data on Comtech

Watch recent presentation from Comtech

PDS Biotechnology Announces Conference Call and Webcast to Present Second Quarter 2021 Financial Results

PDS Biotechnology announced it will release financial results for the second quarter of 2021 on Thursday, August 12, 2021, before the market opens

Research, News & Market Data on PDS Biotechnology

Watch recent presentation from PDS Biotechnology

TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021

TherapeuticsMD announced that it will report its second quarter 2021 financial results on Wednesday, August 4, 2021, before the opening of the U.S. financial markets

Research, News & Market Data on TherapeuticsMD

enCore Energy Announces Group 11 Technologies Update and Webinar

enCore Energy has completed a USD $1 million financing with accredited investors

Research, News & Market Data on enCore Energy

Watch recent presentation from enCore Energy

Stay up to date. Follow us:

Amazon Suspected to be Accepting Bitcoin Soon

Posted on July 26, 2021 by Admin

Is Amazon Getting Primed for Cryptocurrencies?

There has been a lot of uplifting news related to Bitcoin and the prospect of the cryptocurrency becoming mainstreamed. Less than two weeks ago Jack Dorsey the CEO of the fintech powerhouse Square, said Square
is building a decentralized finance business using bitcoin. Last week the Ark Invest sponsored conference named The
B Word featured celebrity CEOs such as Elon Musk and Cathie Wood touting the benefits of Bitcoin. This morning speculators in the asset woke up to a much more subtle reason to be optimistic. Amazon, the mega-giant of online retailers, ran a help wanted ad. The ad was for a “digital currency and blockchain lead.”

Certainty as to what Amazon’s plans are is not available outside the confines of the higher echelons of Amazon. However, the widely embraced hunch is that the open position is to create a team responsible for how Amazon’s customers pay on its platforms. The possibility that the most influential leader in high tech retailing may begin to accept the currency sparked a 12% increase to levels not experienced in six weeks.

“…in this role you will:

· Own the vision and strategy for Amazon’s Digital Currency and Blockchain strategy and product roadmap

· Write documents that work backwards from customer and partner needs
· Dive deep into customer and system data to perform analysis
· Partner effectively with other leaders in product, design, marketing, engineering, science and business intelligence to influence priorities and drive alignment
· Maintain excellent judgment on prioritization between focusing features, architectural improvements and operational excellence

· Monitor project execution and ensuring that the project delivery is to the appropriate levels of quality and in line with target dates

Excerpt from Amazonjobs, Job ID: 1644513

London newspaper City A.M. quoted an anonymous source expressing that the job post is just the surface of a more committed push into the space. “It begins with bitcoin – this is the key first stage of this crypto project, and the directive is coming from the very top… Jeff Bezos himself,” according to the unnamed source. Bezos stepped down as CEO of Amazon in early July. He remains executive chairman of the board of directors. The unnamed source was also quoted by the London paper as saying, “Ethereum, Cardano, and Bitcoin Cash will be next in line before they bring about eight of the most popular cryptocurrencies online.” The source also claimed that Amazon’s crypto push has been in motion since 2019.

Take-Away

There has been a big move in recent weeks by influential CEOs to bring out the full potential of the more widely traded cryptocurrencies. The most recent impacted Bitcoin’s price by 12%, although it is not very definitive what Amazon’s plans are, and reports rely on anonymous sources. Looming over the entire market is the Fed which promised to release a position
paper on cryptocurrency this summer.

The crypto market has been experiencing weakness after reaching highs earlier this year. All of the recent news may have turned the negative trend around.

Suggested Reading:

Bombshells from Musk, Dorsey, and Wood at Bitcoin Conference

Backed by the Full Faith and Credit of Blockchain

Can Wall Street Giants Put Bitcoin on the Menu?

Decentralized Finance, is it the Future?

Sources:

https://www.cityam.com/amazon-definitely-lining-up-bitcoin-payments-and-token-confirms-insider/

https://www.amazon.jobs/en/jobs/1644513/digital-currency-and-blockchain-product-lead

Stay up to date. Follow us:

Release – TherapeuticsMD to Report Second Quarter 2021 Results on August 4 2021

Posted on July 26, 2021 by Admin

TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021

-Executive Management to Host Conference Call on
August 4, 2021 at
8:30 a.m. ET–

BOCA RATON, Fla.–(BUSINESS WIRE)–Jul. 26, 2021–
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its second quarter 2021 financial results on
Wednesday, August 4, 2021, before the opening of the
U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at
8:30 a.m. ET to discuss the Company’s financial results and provide a business update.

Conference Call & Audio Webcast Details

Date	Wednesday, August 4, 2021
Time	8:30 a.m. ET
Telephone Access: U.S. and Canada	866-665-9531
Telephone Access: International	724-987-6977
Access Code For All Callers	7736027
Live Audio Webcast	www.therapeuticsmd.com See Home Page or “Investors & Media” Section

A live webcast and audio archive for the event may be accessed on the home page or from the “Investors & Media” section of the
TherapeuticsMD website at www.therapeuticsmd.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least 30 days. In addition, a digital recording of the conference call will be available for replay beginning two hours after the call’s completion and for at least 30 days with the dial-in 855-859-2056 or international 404-537-3406 and Conference ID: 7736027.

About TherapeuticsMD

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about
TherapeuticsMD, please visit therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook:
TherapeuticsMD.

Forward Looking Statements

This press release by
TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the
Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; whether the company will be able to successfully divest its vitaCare business and the proceeds that may be generated by such divestiture; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; whether the FDA will approve the lower dose of BIJUVA; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership.

Investor Contact

In-Site Communications, Inc.
Lisa M. Wilson
212-452-2793
lwilson@insitecony.com

Media Contact
Kristen Landon
Vice President,
Marketing and Corporate Communications
561-961-1900
Klandon@therapeuticsmd.com

Source:
TherapeuticsMD, Inc.

Release – Comtech Telecommunications Corp. Awarded 35.8 Million Contract to Deploy Next Generation 911 Technologies and Services

Posted on July 26, 2021 by Admin

Comtech Telecommunications Corp. Receives Award from Frost & Sullivan as Growth Leader in Next Generation 911 Technologies and Services

MELVILLE, N.Y.–(BUSINESS WIRE)–Jul. 26, 2021–
July 26, 2021—
Comtech Telecommunications Corp. (NASDAQ: CMTL), a global leading provider of next-generation 911 emergency systems and secure wireless communications technologies, announced that, during its fourth quarter of fiscal 2021, its Safety & Security Technologies (“SST”) group, which is part of Comtech’s Commercial Solutions segment, was awarded a multi-year statewide contract valued at
$35.8 million to design, deploy, and operate Next Generation 911 (“NG911”) services for the
State of Arizona. Total contract value includes a multi-year contract extension option. Excluding such option, the contract is valued at
$23.5 million.

The contract awarded to
Comtech includes implementing Comtech’s NG911 solutions to provide citizens with advanced communication capabilities when calling for emergency services, including police, fire and emergency medical services. Through use of Comtech’s Next Generation Core Services (“NGCS”), the
State of Arizona will be able to offer a seamless, coordinated and efficient NG911 system to all the State’s local 911 centers. The award also includes an ability for
Arizona to purchase Comtech’s market leading Solacom Call Handling solutions for PSAPs and includes Comtech’s new CyberSecurity software training program that will be available for employees on a statewide basis.

“Comtech has a strong presence in
Arizona, having recently expanded operations in Chandler, because of Arizona’s support and focus on business. We are honored that
Comtech has now been entrusted with this important work to enable statewide access to highly reliable advanced communication systems for emergency services for the citizens of
Arizona and are delighted that we will also be able to offer our new CyberSecurity software training solutions to help prevent and reduce cyber-attacks on this mission critical system. We have a long-history of being a partner with the
State of Arizona and are delighted that we have been selected to deliver our market-leading solutions and the highest performance and reliability standards to support mission-critical emergency services,” said Fred Kornberg, Chairman of the Board and Chief Executive Officer of
Comtech Telecommunications Corp.

Comtech’s highly reliable technologies enable the successful handling of over five million 911 calls and texts each month. For more information about Comtech’s 911 products and services, visit www.comtech911.com.

Comtech Telecommunications Corp. is a leading provider of next-generation 911 emergency systems and critical wireless communication technologies to commercial and government customers around the world. Headquartered in
Melville, New York and with a passion for customer success,
Comtech designs, produces and markets advanced and secure wireless solutions to customers in more than 100 countries. For more information, please visit www.comtechtel.com.

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s
Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such
Securities and Exchange Commission filings.

Investor Relations:
631-962-7005
investors@comtech.com

Source:
Comtech Telecommunications Corp.

Genco Shipping Trading Limited (GNK) – Upward Bias Due to Favorable Market Fundamentals

Posted on July 26, 2021 by Admin

Monday, July 26, 2021

Genco Shipping & Trading Limited (GNK)
Upward Bias Due to Favorable Market Fundamentals

Genco Shipping & Trading Limited, incorporated on September 27, 2004, transports iron ore, coal, grain, steel products and other drybulk cargoes along shipping routes through the ownership and operation of drybulk carrier vessels. The Company is engaged in the ocean transportation of drybulk cargoes around the world through the ownership and operation of drybulk carrier vessels. As of December 31, 2016, its fleet consisted of 61 drybulk carriers, including 13 Capesize, six Panamax, four Ultramax, 21 Supramax, two Handymax and 15 Handysize drybulk carriers, with an aggregate carrying capacity of approximately 4,735,000 deadweight tons (dwt). Of the vessels in its fleet, 15 are on spot market-related time charters, and 27 are on fixed-rate time charter contracts. As of December 31, 2016, additionally, 19 of the vessels in its fleet were operating in vessel pools.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2Q2021 Results out AMC on August 4th and Investor Call at 8:30am EST on August 5th.

The call number is 800-430-8332 and code is 8885406. Our 2Q2021 EBITDA estimate is $50.1 million based on TCE rates of $21.0k. We will look for color on: 1) Lagging Cape market and impact of efforts by China to curb inflation; 2) Visibility and tone of Supra/Ultra market; 3) Time charter opportunities; 4) Hedging activity; 5) M&A activity and the cost/timing of recent acquisitions; and 6) Variable dividend policy.

Increasing 2021 EBITDA estimate to $200 million based on TCE rates of $20.2k/day, up from $184 million and TCE rates of $19.1k/day. 2Q2021 forward cover was high with Capes 72% booked at $24.9k/day and Ultras/Supras 76% booked at $17.8k/day so weighted toward 2H2021 estimates. Five time charters signed, but visibility limited …

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021

Posted on July 26, 2021 by Admin

TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021

-Executive Management to Host Conference Call on
August 4, 2021 at
8:30 a.m. ET–

Conference Call & Audio Webcast Details

Date	Wednesday, August 4, 2021
Time	8:30 a.m. ET
Telephone Access: U.S. and Canada	866-665-9531
Telephone Access: International	724-987-6977
Access Code For All Callers	7736027
Live Audio Webcast	www.therapeuticsmd.com See Home Page or “Investors & Media” Section

About TherapeuticsMD

Forward Looking Statements

Investor Contact

In-Site Communications, Inc.
Lisa M. Wilson
212-452-2793
lwilson@insitecony.com

Media Contact
Kristen Landon
Vice President,
Marketing and Corporate Communications
561-961-1900
Klandon@therapeuticsmd.com

Source:
TherapeuticsMD, Inc.

Release – PDS Biotechnology Announces Conference Call and Webcast to Present Second Quarter 2021 Financial Results

Posted on July 26, 2021 by Admin

PDS Biotechnology Announces Conference Call and Webcast to Present Second Quarter 2021 Financial Results

CONTACT: Media & Investor Relations Contact:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital

Release – enCore Energy Announces Group 11 Technologies Update and Webinar

Posted on July 26, 2021 by Admin

enCore Energy Announces Group 11 Technologies Update and Webinar

About Group 11
Technologies Inc.

Group 11 is a group of elements in the periodic table, also known as the
coinage metals, consisting of gold (Au), silver (Ag) and copper (Cu).

About enCore Energy
Corp.

For additional information:

William M. Sheriff

Executive Chairman

972-333-2214

info@encoreenergycorp.com

www.encoreenergycorp.com

Ocugen (OCGN) – Initiating Coverage Based on Covaxin and Novel Gene Therapy Platform

Posted on July 26, 2021 by Admin

Monday, July 26, 2021

Ocugen (OCGN)
Initiating Coverage Based on Covaxin and Novel Gene Therapy Platform

Ocugen Inc is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases.

Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Ocugen is developing products from two technology platforms. The company has in-licensed Covaxin, a whole-virion vaccine for COVID-19 that has advantages over the the current vaccines in use today. Its gene therapy programs are based on delivering “master control” genes that regulate other genes that function in downstream pathways of disease.

Covaxin Has Advantages Over Current Vaccines Covaxin uses a whole-virus technology that stimulates immunity to many regions of the virus. Its clinical trials included over 25,800 patients in Phase 3, with data for patients from ages 12 to 91. The clinical trial data shown efficacy against several new variant strains, included the Delta strain that associated with recent breakthrough cases …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Robinhood’s IPO and its Place in Stock Market History

Posted on July 24, 2021 by Admin

Robinhood’s IPO Success or Failure Could Define the Rest of 2021

Robinhood is one of the most recognized names among Fintech disruptors, especially among investors. The company is scheduled to go public via Initial Public Offering (IPO) Monday (July 26). Then it will begin trading under the ticker symbol HOOD. This allows its customers, and the world, to bid up or bid down Robinhood’s value. The market buzz Monday is going to be mostly about Robinhood. Here is some “stay up to speed” background and details about the transaction. It covers basics to advanced numbers. So you can now be, the more informed co-worker at your watercooler chat (pronounced Zoom meeting), inject the most insight in talks with your investor friends, or just have an easier time deciphering Reddit and Stocktwit posts.

What’s an IPO?

An initial public offering is the most common transition process for a privately owned company to offer corporate shares that trade on open and public markets. It serves to allow private owners to sell all or part of their company and provides management with an enhanced ability to raise capital from public investors. It also allows public investors to own a stake in businesses they deem worthwhile.

Since an IPO is a step that usually provides the company with access to capital that may never exist by other means. This gives the company more options to invest and grow.

About the Robinhood Markets, Inc. IPO

Robinhood is one of the fastest-growing retail securities brokers in the U.S.

In an amended S-1 filed with the Securities and Exchange Commission (SEC), Robinhood provided details about its IPO. The company plans to list its shares on the Nasdaq Exchange using the ticker symbol $HOOD. They will offer 52,375,000 shares of stock, and expect an additional 2,625,000 to be sold by insiders.

Management expects shares to price in a range of $38 to $42. Investor appetite could alter these expectations. At the high end of this range, Robinhood would raise about $2.2 billion, equating to a rough valuation of $35 billion.

Trading Disruptor

Taken straight from its regulatory filing, Robinhood is on a mission “…to democratize finance for all.” The company made trading easier for the smaller transactions of retail investors by pioneering commission-free trades. Other brokers were forced to do the same. This not only dramatically changed the experience for investors, but it also changed the markets in that a huge barrier to entry was lifted. A round trip (buy and later sell) of a stock can be made without needing to factor in commission costs that often made small trades not worth trying. Over the past year, as people had free time on their hands and a stimulus check (or three) in their pocket, many turned to investing for the first time. Robinhood through smart marketing and perceived value became their broker of choice.

Robinhood’s fiscal year ended Dec. 31, 2020, reported revenue of $958.8 million, up 245% compared to 2019. This revenue growth led the company to become profitable — net income grew to $7.4 million, up from a loss of $106.6 million. Other performance indicators improved as well. As of March 31, 2021, the company reported monthly active users of 17.7 million, up 105%, relative to the prior year period. With this, the number of funded accounts rose to 18 million, up from 7.2 million. Robinhood’s assets held in custody grew to $80.9 billion, up more than 400%. For the three months ended March 31, 2021, revenue soared to $522.1 million, or 200% year over year. At the same time, its net loss was reported at $1.4 billion after a special situation. After a round of private equity fundraising in February, the company took a write-down in the fair value of its convertible notes and warrants, resulting in the large loss.

Preliminary second-quarter results suggest its pace of growth has continued. Robinhood is expecting revenue in a range of $546 million to $574 million, which would represent an increase of roughly 130% at the midpoint of its estimate, this would equate to a net loss of roughly $512 million.

For the three months ended June 30, 2021, Robinhood is estimating that its users have grown to 21.3 million, more than double the 10.2 million from the prior-year period. At the same time, the company estimates that its assets held in custody have tripled to $102 billion.

Who Wants to Get Involved in the IPO?

Robinhood is planning to set aside up to 35% of its shares to allow customers to participate in its IPO. Clients can request to buy shares at the IPO price through the app using Robinhood’s IPO Access feature. There are no guarantees as to whether all clients will be able to get filled on their interest.

If it follows the pattern of other IPOs, Robinhood’s stock price will be volatile when it begins trading. There will be a great deal of attention paid to this particular offering. Robinhood has a huge fanbase and almost all of them have trading accounts available in an app on their phone.

Take-Away

The tone of the market this week is likely to be set by the company that helped set the tone of the markets last year, Robinhood. HOOD is likely to become a well followed, closely tracked, perhaps volatile stock. Over time the performance of HOOD could become a harbinger for the health of the retail brokerage market. The activities on Monday, specifically the availability of access to an IPO by small trading accounts, will be paid attention to by everyone from Wall Street giants to first-time account owners.

Paul Hoffman

Managing Editor, Channelchek

Suggested Reading:

Month: July 2021